1Komma5° invests in Heartbeat
Funding Provisional 86% confidence first seen
1KOMMA5° plans to invest more than €100 million into its energy AI platform Heartbeat in 2027, as part of its broader expansion of AI-powered energy management. The coverage ties the planned funding increase to the company’s latest financing round, which valued 1KOMMA5° at $1.35 billion. This matters as it signals continued scaling of Heartbeat’s automation capabilities (e.g., energy trading, billing, and metering) alongside potential US expansion considerations.
The deal
Deal terms as reported in the coverage below.
Decision brief
- What changed
- 1KOMMA5° said it plans to invest more than €100 million in its AI-powered energy management platform Heartbeat in 2027 after a financing round that valued the company at $1.35 billion. The reported purpose is to expand Heartbeat’s automation capabilities across areas such as energy trading, billing, and metering.
- Why it matters
- For business leaders, this is a concrete capital-allocation signal that 1KOMMA5° intends to keep scaling software and automation as a core part of its energy business, not just hardware deployment. That can affect competitive positioning, partnership discussions, and build-versus-buy decisions for companies exposed to distributed energy management. The coverage also links the investment to strategic options such as US expansion and a possible US IPO, which raises the importance of tracking whether Heartbeat becomes the platform through which the company standardizes operations and enters new markets.
- Evidence
- The event is supported by a single Tech.eu report stating that 1KOMMA5° completed a financing round at a $1.35 billion valuation and plans to invest more than €100 million in Heartbeat in 2027. The same report ties the planned investment to broader expansion of energy AI automation and mentions potential US expansion and a possible US IPO, but no second independent source is provided here.
- What remains uncertain
- The coverage does not specify the exact deployment timeline within 2027, expected ROI, product milestones, or how much of the financing round is earmarked directly for Heartbeat. It also does not verify whether US expansion or a US IPO will occur, so any strategic implications beyond the announced investment should be treated as contingent assumptions.
- Monitor next
- Watch for company disclosures on Heartbeat-specific milestones, US market entry steps, or follow-on filings that clarify how the planned €100 million investment will be allocated.
Analytical support, not advice — assumptions and open questions stated above.